Авастин в клинической химиотерапии злокачественных опухолей


Цитировать

Полный текст

Аннотация

Авастин (бевацизумаб) - гуманизированное моноклональное антитело, обладающее выраженной антиангиогенной активностью, прицельно блокирующее сосудистый эндотелиальный фактор роста VEGF и предотвращающее его связывание с рецепторами. Хронологически авастин является одним из первых (вторым после трастузумаба) таргетных препаратов, разрешенных для применения в клинической практике. также он является единственным таргетным препаратом, применяемым при основных злокачественных солидных опухолях: метастатическом колоректальном раке, местно-рецидивирующем или метастатическом раке молочной железы, местно-распространенном, метастатическом или рецидивирующем неплоскоклеточном немелкоклеточном раке легкого, распространенном и/или метастатическом почечно-клеточном раке, глиобластоме (глиома 4-й степени злокачественности по классификации всемирной организации здравоохранения) и эпителиальном раке яичника, маточной трубы и первичном раке брюшины. таким образом, в результате многочисленных исследований авастина в онкологии, проведенных в течение более 10 лет, авастин можно охарактеризовать сегодня двумя словами: первый и лучший, поскольку ни один таргетный препарат не нашел столь широкого клинического применения и показаний в практической онкологии, и, более того, практически ни одно клиническое исследование авастина не было безуспешным. следует сказать также, что большой клинический опыт показывает относительную безопасность препарата в различных подгруппах и популяциях больных.

Об авторах

Вера Андреевна Горбунова

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

зав. отд-нием химиотерапии

Список литературы

  1. Hurwitz H, Fehrenbacher L, Cartwright T et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med 2004; 350 (23): 2335-42.
  2. Saltz L.B, Clarke S, Dнaz-Rubio E et al. Bevacizumab in combination with oxaliplatin - based chemotherapy as first - line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008; 26: 2013-9.
  3. Guan Z.Z, Xu J.M, Luo R.C et al. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: A randomized phase III ARTIST trial. Chin J Cancer 2011; 30: 682-9.
  4. Kabbinavar F, Hurwitz H.I, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-5.
  5. Kabbinavar F.F, Schulz J, Mc Cleod M et al. Addition оf bevacizumab to bolus fluorouracil and leucovorin in first - line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-705.
  6. Tebbutt N.C, Wilson K, Gebski V.J et al. Capecitabine, bevacizumab, and mitomycin in first - line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010; 28: 3191-8.
  7. Giantonio B.J, Catalano P.J, Meropol N.J et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-44.
  8. Hurwitz H, Tebbutt N.C, Kabbinavar F et al. Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials. The Oncologist 2013; 18: 1004-12.
  9. Giantonio B.J, Catalano P.J, Meropol N.J et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-44.
  10. Saltz L.B, Clarke S, Dнaz-Rubio E et al. Bevacizumab in combination with oxaliplatin - based chemotherapy as first - line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008; 26: 2013-9.
  11. Cassidy J, Saltz L.B, Giantonio B.J et al. Effect of bevacizumab in older patients with metastatic colorectal cancer: Pooled analysis of four randomized studies. J Cancer Res Clin Oncol 2010; 136: 737-43.
  12. Welch S, Spithoff K, Rumble R.B et al. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: A systematic review. Ann Oncol 2010; 21: 1152-62.
  13. Price T.J, Zannino D, Wilson K et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: A subgroup analysis from the AGITG MAX trial: An international randomised controlled trial of capecitabine, bevacizumab, and mitomycin C. Ann Oncol 2012; 23: 1531-6.
  14. Bendell J.C, Bekaii-Saab T.S, Cohn A.L et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: Results from ARIES, a bevacizumab observational study. The Oncologist 2012; 17: 1486-95.
  15. Arnold D, Kindler M, Petersen V et al. Bevacizumab plus chemotherapy as first - line treatment for patients with metastatic colorectal cancer: First results from a large community - based observational cohort study in Germany. Presented at: the 2010 Gastrointestinal Symposium; January 22- 24, 2010; Orlando, Florida, USA.
  16. Peeters M, Siena S, Tabernero J. Survival outcomes in the PRIME study for patients (pts) with RAS/BRAF wild - type (WT) metastatic colorectal cancer (mCRC), by baseline Eastern Cooperative Oncology Group (ECOG) performance status (PS). J Clin Oncol 2014; 32 (Suppl.): 5, Abstract 3557.
  17. Rivera F. Extended RAS analysis and subsequent anti-EGFR and anti - VEGF treatment (tx) in PEAK: A first - line phase 2 study of FOLFOX6 + panitumumab (pmab) or bevacizumab (bev) in metastatic colorectal cancer (mCRC). ASCO Annual 2014; Abstract 3629.
  18. Ning Y. Genetic variants of TCF7L2 and AXIN2 predict gender and tumor location - dependent clinical outcome in FIRE-3 trial: A validation study. ASCO Annual Meeting 2014; Abstract 3602.
  19. Martin P, Jung S-H, Johnson J. CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. J Clin Oncol 2014; 32 (Suppl.): 5, Abstract 8521.
  20. Gray R, Bhattacharya S, Bowden C et al. Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer. J Clin Oncol 2009; 27 (30): 4966-72.
  21. Miles D, Chan A, Romieu G et al. Randomized, double - blind, placebo - controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first - line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 2008; 26 (Suppl.): 43.
  22. Robert N.J, Die´ras V, Glaspy J. RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer. J Clin Oncol 2011; 29 (10): 1252-60.
  23. O’Shaughnessy J, Dieras V, Glaspy J et al. Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer (MBC). Cancer Res 2009; 69: 512, Abstract 207.
  24. Miles D.W, Diéras V, Cortés J et al. First - line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 2014; 24 (11): 1-8.
  25. Sandler A, Yi J, Dahlberg S et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non - small cell lung cancer. J Thorac Oncol 2010; 5: 1416-23.
  26. Dansin E et al. ESMO 2010.
  27. Nadler E, Yu E, Ravelo A. Bevacizumab Treatment to Progression After Chemotherapy: Outcomes from a U.S. Community Practice Network. The Oncologist 2011; 16 (4): 486-96.
  28. Burger R.A, Brady M.F, Bookman M.A et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-83.
  29. Perren T, Swart A-M, Pfisterer J et al. A Phase 3 Trial of Bevacizumab in Ovarian Cancer N Engl J Med 2011; 365: 2484-96.
  30. Aghajanian C, Blank S.V, Goff B.A et al: OCEANS: A randomized, double - blind, placebocontrolled phase III trial of chemotherapy with or without bevacizumab in patients with platinumsensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30: 2039-45.
  31. Pujade-Lauraine E, Hilpert F, Weber B et al. Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. J Clin Oncol 2013; 54.
  32. Stupp R, Hegi M.E, Gilbert M.R, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007; 25: 4127-36.
  33. Nghiemphu P.L, Liu W, Lee Y et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single - institution experience. Neurology 2009; 72: 1217-22.
  34. Norden A.D, Young G.S, Setayesh K et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008; 70: 779-87.
  35. Pope W.B, Lai A, Nghiemphu P et al. MRI in patients with high - grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006; 66: 1258-60.
  36. Stark V.V. Bevacizumab (Avastin) and CPT-11 (Camptosar) in the treatment of relapsed malignant glioma (abstract). Neurooncology 2005; 7: 369.
  37. Yung W.K, Albright R.E, Olson J et al. A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83: 588-93.
  38. Wagner S.A, Desjardins A, Reardon D.A, et al. Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas (abstract). J Clin Oncol 2008; 26: 2021.
  39. Vredenburgh J.J, Desjardins A, Herndon 2nd J.E et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13: 1253-9.
  40. Vredenburgh J.J, Desjardins A, Herndon 2nd J.E et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722-9.
  41. Cloughesy T.F, Prados M.D, Mikkelsen T et al. A phase II, randomized, non - comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment - refractory glioblastoma (GBM) (abstract). J Clin Oncol 2008; 26: 2010b.
  42. Kreisl T.N, Kim L, Moore K et al. Phase II trial of single - agent bevacizumab followed by bevacizumab and irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27: 740-5.

© ООО "Консилиум Медикум", 2014

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial 4.0 International License.
 


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах